Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman
29 Maggio 2023 - 7:30AM
Mithra Appoints Experienced Life Sciences Executive Christian
Homsy* as Chairman
- Inge Beernaert appointed President of the Compensation and
Nomination Committee
- Jacques Galloy appointed President of the Audit Committee
Liege, Belgium, 29 May 2023 – 7:30
CEST – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, today announces the appointment of
leading life sciences executive Dr.Christian Homsy as Chairman of
the Board of Directors.
The Board of Directors also appointed Inge
Beernaert as President of the Compensation and Nomination Committee
and Gaudeto, represented by Jacques Galloy as President of the
Audit Committee”
Dr. David Horn Solomon, Chief Executive
Officer of Mithra, commented: “I am delighted that our
board of directors has elected Dr. Christian Homsy as Chairman.
Christian brings valuable competencies and a long record of success
in our industry. His experience provides stability and perspective,
invaluable assets to Mithra during this ongoing transition as we
pursue our ambition to become a global leader in women’s
health.”
Christian Homsy*, who recently joined the Board
as an Independent Director of Mithra, has more than 30 years’
experience in the life sciences industry, most recently as founder
and interim Chief Executive Officer and Board Member of
biotechnology company Capstan Therapeutics. He was also founder,
Chief Executive Officer and Board Member of the Euronext and U.S.
Nasdaq listed Belgian biotechnology company Celyad SA and spent the
first part of his career in senior roles at Guidant Corporation,
now part of Boston Scientific and Abbott. Christian gained his
Medical Doctorate at the University of Louvain, Belgium and his MBA
at IMD Business School, Lausanne, Switzerland.
Dr. Christian Homsy*, Chairman of
Mithra, commented: “I look forward to work closely with
our new CEO David Horn Solomon, the rest of the Mithra leadership
and the newly elected Board of Directors. The new Board of
Directors is fully aligned with the company’s new strategy, shared
by David in his letter to shareholders and discussed last week at
our annual general meeting. The coming period promises to be
transformational for Mithra as we increase our focus on Mithra’s
core strength, development and commercialization of best-in-class
innovative novel therapeutics for women’s health.
“I would also like to thank our outgoing
Directors, Gaetan Servais (Noshaq SA), Amel Tounsi, An Cloet,
Liesbeth Weynants, Patricia van Dijck, Erik Van Den Eynde (Tica
Consult BV) and Christian Morretti (Selva Luxembourg SA) for their
dedication to Mithra and their years of service. Christian Moretti
guided the company with a steady hand, as Chairman, over the last
year and I wish him all the best for the future, on behalf of the
whole Mithra team.”
(*) permanent representative of Life Science
Consulting SRL
For more information, please contact:
Mithra Pharmaceuticals SA David Horn Solomon Chief Executive
Officer investorrelations@mithra.com |
Investor & media relations Chris Maggos Cohesion Bureau
chris.maggos@cohesionbureau.com +41 79 367 6254 |
About Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill Estelle®, Mithra is now
focusing on its second product Donesta®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE®, DONESTA® and MYRING® are registered
trademarks of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
- 2023-05-29_Mithra Appoints Homsy Chair_Final_VFfrench
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Giu 2023 a Giu 2024